Table 3. Comparison of potential risk factors for HSR between patients with no history of HSR and patients with a history of HSR reaction either previously or on trial, grouped together and subgrouped separately.
| No history of any HSR | Any history of HSRa | HSR on studya | HSR before studya | ||||
|---|---|---|---|---|---|---|---|
| |
N=58 (%/range) |
N=29 (%/range) |
P-valueb |
N=18 (%/range) |
P-valueb |
N=15 (%/range) |
P-valueb |
| Median age |
57 (28–80) |
53 (27–73) |
0.11 |
51 (27–73) |
0.09 |
56 (34–73) |
0.5 |
| History of allergy |
26 (44.8) |
18 (62.1) |
0.17 |
9 (50.0) |
0.79 |
10 (66.7) |
0.16 |
| Median platinum-free interval in monthsc |
15.8 |
NA |
NA |
21.4 |
0.2 |
NA |
NA |
| |
(5.7–82.4) |
|
|
(8.5–59.4) |
|
|
|
| Single maximum dose >650 mgc |
10 (17.2) |
NA |
NA |
3 (16.7) |
1 |
NA |
NA |
| Median number of prior carboplatin cycles |
8 (2–42) |
12 (0–23) |
0.47 |
9 (0–19) |
0.85 |
13 (4–23) |
0.079 |
|
BRCA mutation statusd | |||||||
| BRCA1 | 25 (43.1) | 19 (65.5) | 0.069 | 11 (61.1) | 0.28 | 11 (73.3) | 0.046 |
| BRCA2 | 5 (8.6) | 7 (24.1) | 0.095 | 4 (22.2) | 0.2 | 4 (26.7) | 0.079 |
| Any BRCA mutation | 29 (50.0) | 27 (93.1) | <0.0001 | 16 (88.9) | 0.005 | 15 (100) | 0.0002 |
Abbreviations: HSR=hypersensitivity reaction; NA=not applicable.
a
Four patients with prior history of HSR had HSR on study, creating an overlap between patients in the ‘HSR on study' group and ‘HSR before study' group.
b
All P-values compared with no HSR.
c
Platinum-free interval and maximum carboplatin dose >650 mg on trial are relevant only to HSR on trial and were examined in the ‘HSR on study' cohort only; NA = not applicable.
d
One patient had both BRCA1 and 2 mutation and is counted once in ‘any BRCA mutation' cohort; one patient had a BRCAPro of 68% and is counted in ‘any BRCA mutation' cohort, but not in either of ‘BRCA1' or ‘BRCA2' cohorts.